BCI Pharma is delighted to communicate that the company has received a grant from the DG06 (Belgium) to financially support its second research programm.

BCI Pharma is proud to announce that Didier Malherbe accepted his nomination as board chairman. Didier will reinforced BCI structure, participated to BCI development phase and connected to more pharma experts.

BCI Pharma is proud to announce that the company set up a scientific advisor board with experts in neuropathic pain (G. Skouteris and F. Bernhard) and translational function (M. Martiens – Toxicology, G. Mueller – Kinase research).